Innate lymphoid cells in autoimmunity and chronic inflammatory diseases

Abnormal activation of the innate immune system is a common feature of autoimmune and chronic inflammatory diseases. Since their identification as a separate family of leukocytes, innate lymphoid cells (ILCs) have emerged as important effector cells of the innate immune system. Alterations in ILC fu...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in immunopathology 2018-07, Vol.40 (4), p.393-406
Main Authors: Xiong, Tingting, Turner, Jan-Eric
Format: Article
Language:English
Subjects:
Autoimmune diseases
Autoimmunity
Biomedical and Life Sciences
Biomedicine
Effector cells
Immune system
Immunology
Inflammatory bowel diseases
Inflammatory diseases
Innate immunity
Internal Medicine
Intestine
Leukocytes
Lymphoid cells
Multiple sclerosis
Pathophysiology
Psoriasis
Review
Rheumatic diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abnormal activation of the innate immune system is a common feature of autoimmune and chronic inflammatory diseases. Since their identification as a separate family of leukocytes, innate lymphoid cells (ILCs) have emerged as important effector cells of the innate immune system. Alterations in ILC function and subtype distribution have been observed in a variety of immune-mediated diseases in humans and evidence from experimental models suggests a subtype specific role of ILCs in the pathophysiology of autoimmune inflammation. In this review, we discuss recent advances in the understanding of ILC biology in autoimmune and chronic inflammatory disorders, including multiple sclerosis, inflammatory bowel diseases, psoriasis, and rheumatic diseases, with a special focus on the potential of ILCs as therapeutic targets for the development of novel treatment strategies in humans.
ISSN:1863-2297
1863-2300
DOI:10.1007/s00281-018-0670-4